Moreover, a study focusing on gastric mucosa-associated lymphoid tissue (MALT) lymphoma highlighted the potential of [68Ga]Pentixafor PET as a non-invasive alternative to traditional biopsy ...

The final draft of the manuscript was reviewed and approved by all participants. Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease. As a consequence of this, there are no ...

ET-901 is under clinical development by EdiGene and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma). According to GlobalData, ...

ET-901 is under clinical development by EdiGene and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 36% phase ...

an isolated mild sclerodactyly and a Mucosa Associated Lymphoid Tissue (MALT) lymphoma. The scleroderma dot-blot assay was negative. He was the third patient with positive criteria of MCTD by Kasukawa ...

Not all patients had a visit at 6 months after baseline, since this visit was only performed on clinical indication (ie, having a moderate or high disease activity according to ESSDAI, severe ...

The deregulation of the “B-cell lymphoma-2” (BCL2) family in mature B cell malignancies ... mucosa-associated lymphoid tissue (MALT), SMZL, MM, through normalization of Affymetrix Human Genome U133 ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Get Instant Summarized Text (Gist) A clinical trial demonstrated that combining chemotherapy with immunotherapy significantly improves treatment outcomes for diffuse large B-cell lymphoma (DLBCL ...

Hodgkin lymphoma (formerly known as Hodgkin disease), which involves an abnormal type of lymphocyte called Reed-Sternberg cells Non-Hodgkin lymphoma, which does not contain Reed-Sternberg cells ...

Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen ...